NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Efgartigimod for treating antibody-positive generalised myasthenia gravis (review of TA1069) [GID-TA12493]

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Argenx (efgartigimod) Patient/carer groups • Arthritis and Musculoskeletal Alliance • Brain and Spine Foundation • Brain Charity • Genetic Alliance UK • Muscular Dystrophy UK • Myaware • Neuro Therapy Network • Neurological Alliance • Pathfinders Neuromuscular Alliance • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • Association of Anaesthetists of Great Britain and Ireland • Association of British Neurologists • British Association of Neuroscience Nurses • British Geriatrics Society • British Myology Society • British Neuropathological Society • British Neuropsychiatry Association • British Paediatric Neurology Association • British Society for Clinical Neurophysiology • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • National Neurosciences Advisory Group	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary (BNF) • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • MHRA • National Association of Primary Care • National Pharmacy Association • National Services Division - Commissioning for Scotland's Health • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • Grifols UK (IVIg) • Octapharma (IVIg) • Takeda UK (IVIg) • UCB Pharma (rozanolixizumab) • UCB Pharma (zilucoplan) Relevant research groups • Brain Research UK

Provisional Consultees	**Provisional Commentators (no right to submit or appeal)**
• Physiotherapy Pain Association • Primary Care and Community Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Pharmacy • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • The Royal College of Pathologists • UK Clinical Pharmacy Association (UKCPA) <u>Others</u> • Department of Health and Social Care • NHS England	• Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England • Institute of Neurology • MRC Clinical Trials Unit • National Hospital for Neurology & Neurosurgery • National Institute for Health & Care Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

